Abstract
Glucocorticoids have been widely used in the treatment of autoimmune and other diseases. Chronic steroid use, however, could cause proximal muscle weakness and atrophy, termed steroid myopathy. The onset of steroid myopathy is usually insidious and there are no specific laboratory findings except for elevated urinary creatine excretion. Muscle biopsy reveals non-specific type II fiber atrophy. There are many reports showing preventive effects of either growth hormone (GH) or insulin-like growth factor (IGF)-I on steroid myopathy. The pathogenesis of steroid myopathy is not fully understood. Recently, glutamine synthetase has been reported to play a key role in steroid myopathy. GH as well as IGF-I decreased the steroid-induced glutamine synthetase activity in skeletal muscle.
Journal Section:
Paper
References
1.
Kaplan PW, Rocha W, Sanders DB, D’Souza B, Spock A: Acute steroid-induced tetraplegia following status asthmaticus. Pediatrics 1986;78:121–123.
[PubMed]
2.
Danon MJ, Carpenter S: Myopathy with thick filament (myosin) loss following prolonged paralysis with vecuronium during steroid treatment. Muscle Nerv 1991;14:1131–1139.
[PubMed]
3.
Zochodne DW, Ramsay DA, Saly V, Shelley S, Moffatt S: Acute necrotizing myopathy of intensive care: electrophysiologic studies. Muscle Nerv 1994;17:285–292.
[PubMed]
4.
Askari A, Vignos PJ Jr, Moskowitz RW: Steroid myopathy in connective tissue disease. Am J Med 1976;61:485–492.
[PubMed]
5.
Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM: Steroid myopathy in cancer patients. Neurology 1997;48:1234–1238.
[PubMed]
6.
Kissel JT, Mendell JR: The endocrine myopathies; in Rowland LP, Dimauro S (eds): Handbook of Clinical Neurology. Amsterdam, Elsevier Science, 1992, vol 18(62), pp 527–551.
7.
Braunstein PW Jr, DeGirolami U: Experimental corticosteroid myopathy. Acta Neuropathol 1981;55:167–172.
[PubMed]
8.
Horber FF, Scheidegger JR, Grunig BE, Frey FJ: Evidence that prednisone-induced myopathy is reversed by physical training. J Clin Endocrinol Metab 1985;61:83–88.
[PubMed]
9.
Shoji S, Takagi A, Sugita H, Toyokura Y: Muscle glycogen metabolism in steroid-induced myopathy of rabbits. Exp Neurol 1974;45:1–7.
[PubMed]
10.
Fernandez-Sola J, Cusso R, Picado C, Vernet M, Grau JM, Urbano-Marquez A: Patients with chronic glucocorticoid treatment develop changes in muscle glycogen metabolism. J Neurol Sci 1993;117:103–106.
[PubMed]
11.
Wagenmakers AJM: Protein and amino acid metabolism in human muscle. Adv Exp Med Biol 1998;441:307–319.
[PubMed]
12.
Smith RJ, Larson S, Stred SE, Durschlag RP: Regulation of glutamine synthetase and glutaminase activities in cultured skeletal muscle cells. J Cell Physiol 1984;120:197–203.
[PubMed]
13.
Max SR, Mill J, Mearow K, Konagaya M, Konagaya Y, Thomas JW, Banner C, Vitkovic L: Dexamethasone regulates glutamine synthetase expression in rat skeletal muscles. Am J Physiol 1988;255:E397–E402.
[PubMed]
14.
Zhang H, Young AP: Exogenous but not endogenous, glucocorticoid receptor induces glutamine synthetase gene expression in early stage embryonic retina. J Biol Chem 1993;268:2850–2856.
[PubMed]
15.
Chandrasekhar S, Souba WW, Abcouwer SF: Identification of glucocorticoid-responsive elements that control transcription of rat glutamine synthetase. Am J Physiol 1999;276:L319–L331.
[PubMed]
16.
Labow BI, Souba WW, Abcouwer SF: Glutamine synthetase expression in muscle is regulated by transcriptional and posttranscriptional mechanisms. Am J Physiol 1999;276:E1136–E1145.
[PubMed]
17.
Hickson RC, Czerwinski SM, Wegrzyn LE: Glutamine prevents downregulation of myosin heavy chain synthesis and muscle atrophy from glucocorticoids. Am J Physiol 1995;268:E730–E734.
[PubMed]
18.
Ullman M, Oldfors A: Effects of growth hormone on skeletal muscle. I. Studies on normal adult rats. Acta Physiol Scand 1989;135:531–536.
[PubMed]
19.
Crist DM, Peake GT, Loftfield RB, Kraner JC, Egan PA: Supplemental growth hormone alters body composition, muscle protein metabolism and serum lipids in fit adults: characterization of dose-dependent and response-recovery effects. Mech Ageing Dev 1991;58:191–205.
[PubMed]
20.
Tashjian AH Jr, Bancroft FC, Levine L: Production of both prolactin and growth hormone by clonal strains of rat pituitary tumor cells. Differential effects of hydrocortisone and tissue extracts. J Cell Biol 1970;47:61–70.
[PubMed]
21.
Riss TL, Novakofski J, Bechtel PJ: Skeletal muscle hypertrophy in rats having growth hormone-secreting tumor. J Appl Physiol 1986;61:1732–1735.
[PubMed]
22.
Prysor-Jones RA, Jenkins JS: Effect of excessive secretion of growth hormone on tissues of the rat, with particular reference to the heart and skeletal muscle. J Endocrinol 1980;85:75–82.
[PubMed]
23.
Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ: Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999;341:785–792.
[PubMed]
24.
Kaiser FE, Silver AJ, Morley JE: The effect of recombinant human growth hormone on malnourished older individuals. J Am Geriatr Soc 1991;39:235–240.
[PubMed]
25.
Lanz JK Jr, Donahoe M, Rogers RM, Ontell M: Effects of growth hormone on diaphragmatic recovery from malnutrition. J Appl Physiol 1992;73:801–805.
[PubMed]
26.
Manson JM, Smith RJ, Wilmore DW: Growth hormone stimulates protein synthesis during hypocaloric parenteral nutrition. Role of hormonal-substrate environment. Ann Surg 1988;208:136–142.
[PubMed]
27.
Wolf RF, Pearlstone DB, Newman E, Heslin MJ, Gonenne A, Burt ME, Brennan MF: Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients. Ann Surg 1992;216:280–290.
[PubMed]
28.
Ullman M, Alameddine H, Skottner A, Oldfors A: Effects of growth hormone on skeletal muscle. II. Studies on regeneration and denervation in adult rats. Acta Physiol Scand 1989;135:537–543.
[PubMed]
29.
Horber FF, Haymond MW: Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest 1990;86:265–272.
[PubMed]
30.
Kovacs G, Fine RN, Worgall S, Schaefer F, Hunziker EB, Skottner-Lindun A, Mehls O: Growth hormone prevents steroid-induced growth depression in health and uremia. Kidney Int 1991;40:1032–1040.
[PubMed]
31.
Matsushita T, Kanda F, Sugio T, Okuda S, Chihara K: Growth hormone prevents the steroid myopathy in rats. Clin Neurol (Tokyo) 1996;36:752–756.
32.
Tomas FM, Murray AJ, Jones LM: Modification of glucocorticoid-induced changes in myofibrillar protein turnover in rats by protein and energy deficiency as assessed by urinary excretion of Ntau-methylhistidine. Br J Nutr 1984;51:323–337.
[PubMed]
33.
Florini JR, Ewton DZ, Coolican SA: Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev 1996;17:481–517.
[PubMed]
34.
Haymond MW, Horber FF, Mauras N: Human growth hormone but not insulin-like growth factor I positively affects whole-body estimates of protein metabolism. Horm Res 1992;38(suppl 1):73–75.
35.
Mauras N, O’Brien KO, Welch S, Rini A, Helgeson K, Vieira NE, Yergey AL: Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, calcium metabolism. J Clin Endocrinol Metab 2000;85:1686–1694.
[PubMed]
36.
Fryburg DA, Gelfand RA, Barrett EJ: Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans. Am J Physiol 1991;260:E499–E504.
[PubMed]
37.
Vandenburgh HH, Karlisch P, Shansky J, Feldstein R: Insulin and IGF-I induce pronounced hypertrophy of skeletal myofibers in tissue culture. Am J Physiol 1991;260:C475–C484.
[PubMed]
38.
Zdanowicz MM, Moyse J, Wingertzahn MA, O’Connor M, Teichberg S, Slonim AE: Effect of insulin-like growth factor I in murine muscular dystrophy. Endocrinology 1995;136:4880–4886.
[PubMed]
39.
Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL: Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA 1998;95:15603–15607.
[PubMed]
40.
Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Read LC, Ballard FJ: Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J 1992;282:91–97.
[PubMed]
41.
Kanda F, Takatani K, Okuda S, Matsushita T, Chihara K: Preventive effects of insulin-like growth factor-I on steroid-induced muscle atrophy. Muscle Nerv 1999;22:213–217.
[PubMed]
42.
Florini JR, Ewton DZ, Roof SL: Insulin-like growth factor-I stimulates terminal myogenic differentiation by induction of myogenin gene expression. Mol Endocrinol 1991;5:718–724.
[PubMed]
43.
Chakravarthy MV, Davis BS, Booth FW: IGF-I restores satellite cell proliferative potential in immobilized old skeletal muscle. J Appl Physiol 2000;89:1365–1379.
[PubMed]
44.
Liu J-P, Baker J, Perkins AS, Robertson EJ, Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factors I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993;75:59–72.
[PubMed]
45.
Fournier M, Lewis MI: Influences of IGF-I gene disruption of the cellular profile of the diaphragm. Am J Physiol 2000;278:E707–E715.
46.
Falduto MT, Young AP, Hickson RC: Exercise inhibits glucocorticoid-induced glutamine synthetase expression in rat skeletal muscles. Am J Physiol 1992;262:C214–C220.
[PubMed]
47.
Falduto MT, Young AP, Hickson RC: Exercise interrupts ongoing glucocorticoid-induced muscle atrophy and glutamine synthetase induction. Am J Physiol 1992;263:E1157–E1163.
[PubMed]
48.
Biolo G, Iscra F, Bosutti A, Toigo G, Ciocchi B, Geatti O, Gullo A, Guarnieri G: Growth hormone decreases muscle glutamine production and stimulates protein synthesis in hypercatabolic patients. Am J Physiol 2000;279:E323–E332.
49.
Parry-Billings M, Bevan SJ, Opara E, Liu C-T, Dunger DB, Newsholme EA: The effects of growth hormone and insulin-like growth factors I and II on glutamine metabolism by skeletal muscle of the rat in vitro. Horm Metab Res 1993;25:243–245.
[PubMed]
50.
Kimura K, Kanda F, Okuda S, Chihara K: Insulin-like growth factor 1 inhibits glucocorticoid-induced glutamine synthetase activity in cultured L6 rat skeletal muscle cells. Neurosci Lett 2001;302:154–156.
[PubMed]
51.
Coolican SA, Samuel DS, Ewton DZ, McWade FJ, Florini JR: The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem 1997;272:6653–6662.
[PubMed]
52.
Friday BB, Horsley V, Pavlath GK: Calcineurin activity is required for the initiation of skeletal muscle differentiation. J Cell Biol 2000;149:657–665.
[PubMed]
53.
Delling U, Tureckova J, Lim HW, De Windt LJ, Rotwein P, Molkentin JD: A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavy-chain expression. Mol Cell Biol 2000;20:6600–6611.
[PubMed]
54.
Chin ER, Olson EN, Richardson JA, Yang Q, Humphries C, Shelton JM, Wu H, Zhu W, Bassel-Duby R, Wiliams RS: A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev 1998;12:2499–2509.
[PubMed]
55.
Dunn SE, Burns JL, Michel RN: Calcineurin is required for skeletal muscle hypertrophy. J Biol Chem 1999;274:21908–21912.
[PubMed]
56.
Semsarian C, Wu MJ, Ju YK, Marciniec T, Yeoh T, Allen DG, Harvey RP, Graham RM: Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin signaling pathway. Nature 1999;400:576–581.
[PubMed]
57.
Musaro A, McCullagh KJA, Naya FJ, Olson EN, Rosenthal N: IGF-1 induces skeletal muscle hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 1999;400:581–585.
[PubMed]
58.
Kaliman P, Canicio J, Shepherd PR, Beeton CA, Testar X, Palacin M, Zorzano A: Insulin-like growth factors require phosphatidylinositol 3-kinase to signal myogenesis: dominant negative p85 expression blocks differentiation of L6E9 muscle cells. Mol Endocrinol 1998;12:66–77.
[PubMed]
59.
Singleton JR, Baker BL, Thorburn A: Dexamethasone inhibits insulin-like growth factor signaling and potentiates myoblast apoptosis. Endocrinology 2000;141:2945–2950.
[PubMed]
© 2001 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2001
You do not currently have access to this content.
